I am a
Home I AM A Search Login

Papers of the Week


2021 Mar 11


Hepatology

Safety, pharmacokinetics, and pharmacodynamics of the oral TLR8 agonist selgantolimod in chronic hepatitis B.

Authors

Gane EJ, Kim H J, Visvanathan K, Kim Y J, Nguyen A-H, Wallin JJ, Chen DY, McDonald C, Arora P, Tan SK, Gaggar A, Roberts SK, Lim Y-S
Hepatology. 2021 Mar 11.
PMID: 33704806.

Abstract

In patients with chronic hepatitis B (CHB) infection, activation of toll-like receptor 8 (TLR8) may induce antiviral immunity and drive functional cure. Selgantolimod, a novel TLR8 agonist, was evaluated in CHB patients who were virally suppressed on oral antiviral treatment (OAV) or viremic not on OAV.